Publications by authors named "Jordan E Eicholz"
Article Synopsis
- In a study of 328 patients with stage III non-small cell lung cancer (NSCLC) undergoing concurrent chemoradiation and durvalumab treatment, high PD-L1 expression (≥90%) and elevated tumor mutational burden (TMB) were found to enhance disease control.
- The timing of pneumonitis onset significantly affected patient outcomes; those with late-onset pneumonitis had longer progression-free survival (PFS) and overall survival compared to those with early-onset pneumonitis.
- The research indicates potential strategies to improve treatment outcomes for patients with lower PD-L1 and TMB levels, especially those at risk for pneumonitis.
